DEFB105A
gene geneOn this page
Also known as DEFB-5
Summary
DEFB105A (defensin beta 105A, HGNC:18087) is a protein-coding gene on chromosome 8p23.1, encoding Beta-defensin 105 (Q8NG35). Has antibacterial activity.
Defensins form a family of antimicrobial and cytotoxic peptides made by neutrophils. Defensins are short, processed peptide molecules that are classified by structure into three groups: alpha-defensins, beta-defensins and theta-defensins. All beta-defensin genes are densely clustered in four to five syntenic chromosomal regions. Chromosome 8p23 contains at least two copies of the duplicated beta-defensin cluster. This duplication results in two identical copies of defensin, beta 105, DEFB105A and DEFB105B, in tail-to-tail orientation. This gene, DEFB105A, represents the more centromeric copy.
Source: NCBI Gene 245908 — RefSeq curated summary.
At a glance
- Clinical variants (ClinVar): 8 total
- MANE Select transcript:
NM_152250
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:18087 |
| Approved symbol | DEFB105A |
| Name | defensin beta 105A |
| Location | 8p23.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Aliases | DEFB-5 |
| Ensembl gene | ENSG00000186562 |
| Ensembl biotype | protein_coding |
| Entrez | 245908 |
Gene structure
Transcript identifiers
Ensembl transcripts: 1 — 1 protein_coding
ENST00000334773
RefSeq mRNA: 1 — MANE Select: NM_152250
NM_152250
CCDS: CCDS34832
Canonical transcript exons
ENST00000334773 — 3 exons
| Exon | Start | End |
|---|---|---|
| ENSE00001674146 | 7821004 | 7822132 |
| ENSE00001794453 | 7823382 | 7823423 |
| ENSE00002172401 | 7823769 | 7823880 |
Expression profiles
Bgee: expression breadth broad, 28 present calls, max score 37.20.
Top tissues by expression
124 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| colonic epithelium | UBERON:0000397 | 37.20 | gold quality |
| ventricular zone | UBERON:0003053 | 36.48 | gold quality |
| cortical plate | UBERON:0005343 | 36.47 | gold quality |
| bone marrow cell | CL:0002092 | 36.16 | gold quality |
| ganglionic eminence | UBERON:0004023 | 35.49 | gold quality |
| skeletal muscle tissue | UBERON:0001134 | 33.38 | gold quality |
| muscle tissue | UBERON:0002385 | 33.08 | silver quality |
| hindlimb stylopod muscle | UBERON:0004252 | 32.15 | gold quality |
| bone marrow | UBERON:0002371 | 31.74 | gold quality |
| stromal cell of endometrium | CL:0002255 | 29.87 | gold quality |
| prefrontal cortex | UBERON:0000451 | 29.04 | gold quality |
| duodenum | UBERON:0002114 | 28.14 | gold quality |
| liver | UBERON:0002107 | 28.04 | gold quality |
| lymph node | UBERON:0000029 | 27.57 | gold quality |
| blood | UBERON:0000178 | 27.08 | gold quality |
| tonsil | UBERON:0002372 | 27.05 | gold quality |
| leukocyte | CL:0000738 | 26.55 | gold quality |
| islet of Langerhans | UBERON:0000006 | 26.55 | gold quality |
| monocyte | CL:0000576 | 26.45 | gold quality |
| vermiform appendix | UBERON:0001154 | 26.42 | gold quality |
| gall bladder | UBERON:0002110 | 25.98 | gold quality |
| olfactory segment of nasal mucosa | UBERON:0005386 | 25.89 | gold quality |
| placenta | UBERON:0001987 | 25.81 | gold quality |
| urinary bladder | UBERON:0001255 | 25.72 | gold quality |
| cortex of kidney | UBERON:0001225 | 25.53 | gold quality |
| endometrium | UBERON:0001295 | 24.65 | silver quality |
| primary visual cortex | UBERON:0002436 | 24.61 | gold quality |
| superior frontal gyrus | UBERON:0002661 | 24.08 | gold quality |
| kidney | UBERON:0002113 | 23.95 | gold quality |
| pancreas | UBERON:0001264 | 23.89 | gold quality |
Single-cell (SCXA)
Detected in 2 experiment(s), a significant marker in 0.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-HCAD-38 | no | 2600.27 |
| E-ANND-3 | no | 0.07 |
Regulation
Is transcription factor: no
Literature-anchored findings (GeneRIF, showing 3)
- The epididymis-specific expression pattern of the beta-defensin isoform BD-5 has been characterized. (PMID:12193721)
- Defensin-beta 105 displays antimicrobial activity against S. aureus and E. coli, among other bacteria. (PMID:21861459)
- The native disulfide array of human defensin 5 is a requirement for its activity against Staphylococcus aureus. (PMID:21861459)
Cross-species orthologs
4 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| mus_musculus | Defb12 | ENSMUSG00000043787 |
| mus_musculus | Defb35 | ENSMUSG00000058052 |
| rattus_norvegicus | Defb105b | ENSRNOG00000083461 |
| rattus_norvegicus | Defb105a | ENSRNOG00000090398 |
Paralogs (1): DEFB105B (ENSG00000186599)
Protein
Protein identifiers
Beta-defensin 105 — Q8NG35 (reviewed: Q8NG35)
Alternative names: Beta-defensin 5, Defensin, beta 105
All UniProt accessions (2): Q8NG35, A0A0K0K1I4
UniProt curated annotations — full annotation on UniProt →
Function. Has antibacterial activity.
Subcellular location. Secreted.
Tissue specificity. Specifically expressed in testis.
Similarity. Belongs to the beta-defensin family.
RefSeq proteins (1): NP_689463* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR025933 | Beta_defensin_dom | Domain |
Pfam: PF13841
UniProt features (5 total): disulfide bond 3, signal peptide 1, peptide 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q8NG35-F1 | 72.22 | 0.11 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Disulfide bonds (3): 43–74, 53–67, 57–73
Function
Pathways and Gene Ontology
Reactome pathways
2 pathways
| ID | Pathway |
|---|---|
| R-HSA-1461957 | Beta defensins |
| R-HSA-1461973 | Defensins |
MSigDB gene sets: 11 (showing top):
REACTOME_INNATE_IMMUNE_SYSTEM, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, GOBP_DEFENSE_RESPONSE_TO_BACTERIUM, ACEVEDO_METHYLATED_IN_LIVER_CANCER_DN, GOBP_RESPONSE_TO_BACTERIUM, REACTOME_ANTIMICROBIAL_PEPTIDES, SCHERER_PBMC_YF_VAX_AGE_18_40YO_4_TO_7DY_UP, GOBP_BIOLOGICAL_PROCESS_INVOLVED_IN_INTERSPECIES_INTERACTION_BETWEEN_ORGANISMS, REACTOME_DEFENSINS, REACTOME_BETA_DEFENSINS, chr8p23
GO Biological Process (3): defense response to bacterium (GO:0042742), innate immune response (GO:0045087), defense response (GO:0006952)
GO Molecular Function (0):
GO Cellular Component (1): extracellular region (GO:0005576)
Reactome top-level categories
Rollup of top-2 pathways:
| Category | Pathways |
|---|---|
| Defensins | 1 |
| Antimicrobial peptides | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| defense response | 1 |
| response to bacterium | 1 |
| immune response | 1 |
| defense response to symbiont | 1 |
| response to stress | 1 |
| cellular anatomical structure | 1 |
Protein interactions and networks
STRING
184 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| DEFB105A | DEFB106A | Q8N104 | 928 |
| DEFB105A | DEFB104A | Q8WTQ1 | 914 |
| DEFB105A | DEFB107A | Q8IZN7 | 883 |
| DEFB105A | DEFB103A | P81534 | 880 |
| DEFB105A | A0A0G2JN59 | A0A0G2JN59 | 832 |
| DEFB105A | DEFB108B | Q8NET1 | 815 |
| DEFB105A | DEFB1 | P60022 | 811 |
| DEFB105A | DEFB4A | O15263 | 697 |
| DEFB105A | PRR23D1 | E9PI22 | 583 |
| DEFB105A | DEFB110 | Q30KQ9 | 570 |
| DEFB105A | DEFB126 | Q9BYW3 | 552 |
| DEFB105A | DEFA5 | Q01523 | 546 |
| DEFB105A | USP17L4 | A6NCW7 | 518 |
| DEFB105A | FAM90A7 | A6NKC0 | 515 |
| DEFB105A | PRR23B | Q6ZRT6 | 509 |
IntAct
3 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| DEFB105A | psi-mi:“MI:0915”(physical association) | 0.560 | |
| DEFB105A | psi-mi:“MI:0915”(physical association) | 0.000 |
BioGRID (2): DEFB105A (Two-hybrid), DEFB105B (Two-hybrid)
ESM2 similar proteins: A0A096LNP1, A4H206, A4H207, A4H208, A4H209, A4H212, A4H213, P0C8A5, P0C8B0, P0DP73, P0DP74, P59861, P82020, P82172, Q30KJ3, Q30KJ5, Q30KJ6, Q30KJ8, Q30KJ9, Q30KK8, Q30KL4, Q30KL6, Q30KM9, Q30KP5, Q30KP6, Q30KP8, Q30KQ1, Q30KQ6, Q30KQ7, Q30KQ9, Q32ZF3, Q32ZF7, Q32ZG3, Q32ZH4, Q32ZH5, Q32ZH6, Q32ZI1, Q32ZI2, Q4QY38, Q6QLQ7
Diamond homologs: A4H206, A4H207, A4H208, A4H209, Q30KQ1, Q32ZH6, Q32ZH9, Q5IAB6, Q8K4N3, Q8NG35, Q8R2I3, Q30KJ6, Q30KU3, Q30KQ6, Q32ZH8
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
8 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 4 |
| Likely benign | 2 |
| Benign | 2 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
363 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 8:7823378:TTACC:T | donor_loss | 0.9900 |
| 8:7823379:TACCT:T | donor_loss | 0.9900 |
| 8:7823380:A:AT | donor_loss | 0.9900 |
| 8:7823765:TTACC:T | donor_loss | 0.9900 |
| 8:7823766:TACC:T | donor_loss | 0.9900 |
| 8:7823767:A:AC | donor_gain | 0.9900 |
| 8:7823767:A:AT | donor_loss | 0.9900 |
| 8:7823768:C:CC | donor_gain | 0.9900 |
| 8:7823768:C:CG | donor_loss | 0.9900 |
| 8:7823823:T:TA | donor_gain | 0.9900 |
| 8:7823421:ACCC:A | acceptor_loss | 0.9800 |
| 8:7823422:CC:C | acceptor_gain | 0.9800 |
| 8:7823423:CC:C | acceptor_gain | 0.9800 |
| 8:7823424:CTAA:C | acceptor_loss | 0.9800 |
| 8:7823425:T:A | acceptor_loss | 0.9800 |
| 8:7822202:C:CT | acceptor_gain | 0.9700 |
| 8:7822205:C:CT | acceptor_gain | 0.9700 |
| 8:7823377:CTTA:C | acceptor_loss | 0.9700 |
| 8:7823378:TTA:T | acceptor_loss | 0.9700 |
| 8:7823379:TACC:T | acceptor_loss | 0.9700 |
| 8:7823380:A:AG | acceptor_loss | 0.9700 |
| 8:7823420:CACC:C | acceptor_gain | 0.9700 |
| 8:7823424:C:CC | acceptor_gain | 0.9700 |
| 8:7823767:AC:A | donor_gain | 0.9700 |
| 8:7823768:CC:C | donor_gain | 0.9700 |
| 8:7823768:CCT:C | donor_gain | 0.9700 |
| 8:7822206:A:T | acceptor_gain | 0.9600 |
| 8:7823376:ACTT:A | acceptor_loss | 0.9600 |
| 8:7823380:A:AC | donor_gain | 0.9600 |
| 8:7823381:C:CC | donor_gain | 0.9600 |
AlphaMissense
509 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 8:7822087:C:G | C53S | 0.941 |
| 8:7822088:A:T | C53S | 0.941 |
| 8:7822108:C:G | C46S | 0.916 |
| 8:7822109:A:T | C46S | 0.916 |
| 8:7822088:A:G | C53R | 0.912 |
| 8:7822076:A:G | C57R | 0.899 |
| 8:7822075:C:G | C57S | 0.897 |
| 8:7822076:A:T | C57S | 0.897 |
| 8:7822045:C:G | C67S | 0.895 |
| 8:7822046:A:T | C67S | 0.895 |
| 8:7822027:C:G | C73S | 0.894 |
| 8:7822028:A:T | C73S | 0.894 |
| 8:7822108:C:T | C46Y | 0.893 |
| 8:7822024:C:G | C74S | 0.881 |
| 8:7822025:A:T | C74S | 0.881 |
| 8:7822086:G:C | C53W | 0.862 |
| 8:7822028:A:G | C73R | 0.861 |
| 8:7822026:G:C | C73W | 0.860 |
| 8:7822044:G:C | C67W | 0.845 |
| 8:7822109:A:G | C46R | 0.843 |
| 8:7822046:A:G | C67R | 0.841 |
| 8:7822107:G:C | C46W | 0.838 |
| 8:7822074:G:C | C57W | 0.834 |
| 8:7822108:C:A | C46F | 0.827 |
| 8:7822023:G:C | C74W | 0.823 |
| 8:7822118:A:G | C43R | 0.823 |
| 8:7822087:C:T | C53Y | 0.820 |
| 8:7822025:A:G | C74R | 0.817 |
| 8:7822087:C:A | C53F | 0.810 |
| 8:7822117:C:G | C43S | 0.806 |
dbSNP variants (sampled 300 via entrez): RS1000234208 (8:7823030 C>T), RS1010340219 (8:7821456 C>G,T), RS1020354130 (8:7822042 C>T), RS1024826176 (8:7824724 C>G,T), RS112399468 (8:7824719 CTT>C), RS113792280 (8:7822603 T>A), RS1156451028 (8:7823439 A>G), RS1156552300 (8:7824850 A>G), RS1157488093 (8:7821094 T>G), RS1157708231 (8:7823315 C>G,T), RS1157848324 (8:7821274 T>C), RS1158329291 (8:7821713 G>C), RS1158788226 (8:7825141 T>C), RS1159258551 (8:7821751 T>G), RS1159772138 (8:7821289 A>C)
Disease associations
OMIM: gene `` | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
0 associations (top):
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
2 total (human), top 2 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| CGP 52608 | affects binding, increases reaction | 1 |
| Aflatoxin B1 | increases methylation | 1 |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.